BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24144412)

  • 21. Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues.
    Silva FT; Franco CH; Favaro DC; Freitas-Junior LH; Moraes CB; Ferreira EI
    Eur J Med Chem; 2016 Oct; 121():553-560. PubMed ID: 27318979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo studies of the trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruzi.
    da Silva CF; Batista MM; Batista Dda G; de Souza EM; da Silva PB; de Oliveira GM; Meuser AS; Shareef AR; Boykin DW; Soeiro Mde N
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3307-14. PubMed ID: 18625779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural and synthetic naphthoquinones active against Trypanosoma cruzi: an initial step towards new drugs for Chagas disease.
    Salas CO; Faúndez M; Morello A; Maya JD; Tapia RA
    Curr Med Chem; 2011; 18(1):144-61. PubMed ID: 21110810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chagas Disease and Coumarins: A Review of Natural and Synthetic Coumarins As Anti-Trypanosoma Cruzi Agents.
    Gonçalves GA; Cerecetto H; Poser GLV; Canto RFS; Eifler-Lima VL
    Mini Rev Med Chem; 2021; 21(13):1701-1717. PubMed ID: 33372872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.
    da Silva EB; Oliveira E Silva DA; Oliveira AR; da Silva Mendes CH; Dos Santos TA; da Silva AC; de Castro MC; Ferreira RS; Moreira DR; Cardoso MV; de Simone CA; Pereira VR; Leite AC
    Eur J Med Chem; 2017 Apr; 130():39-50. PubMed ID: 28242550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-T. cruzi agents: our experience in the evaluation of more than five hundred compounds.
    Cerecetto H; González M
    Mini Rev Med Chem; 2008 Nov; 8(13):1355-83. PubMed ID: 18991753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
    Melo-Filho CC; Braga RC; Muratov EN; Franco CH; Moraes CB; Freitas-Junior LH; Andrade CH
    Eur J Med Chem; 2019 Feb; 163():649-659. PubMed ID: 30562700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current advances in drug discovery for Chagas disease.
    Scarim CB; Jornada DH; Chelucci RC; de Almeida L; Dos Santos JL; Chung MC
    Eur J Med Chem; 2018 Jul; 155():824-838. PubMed ID: 30033393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations.
    Leite DI; Fontes FV; Bastos MM; Hoelz LVB; Bianco MDCAD; de Oliveira AP; da Silva PB; da Silva CF; Batista DDGJ; da Gama ANS; Peres RB; Villar JDF; Soeiro MNC; Boechat N
    Chem Biol Drug Des; 2018 Sep; 92(3):1670-1682. PubMed ID: 29745048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
    Palace-Berl F; Pasqualoto KFM; Zingales B; Moraes CB; Bury M; Franco CH; da Silva Neto AL; Murayama JS; Nunes SL; Silva MN; Tavares LC
    Eur J Med Chem; 2018 Jan; 144():29-40. PubMed ID: 29247858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
    Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H
    Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo activity of the chloroaryl-substituted imidazole viniconazole against Trypanosoma cruzi.
    Silva CF; Batista Dda G; Batista MM; Lionel J; Hammer ER; Brun R; Soeiro Mde N
    Parasitology; 2014 Mar; 141(3):367-73. PubMed ID: 24553079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
    Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
    Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Trypanosoma cruzi activity of costic acid isolated from Nectandra barbellata (Lauraceae) is associated with alterations in plasma membrane electric and mitochondrial membrane potentials.
    Londero VS; Costa-Silva TA; Tempone AG; Namiyama GM; Thevenard F; Antar GM; Baitello JB; Lago JHG
    Bioorg Chem; 2020 Jan; 95():103510. PubMed ID: 31884137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and Optimization of a Compound Series Active against
    Harrison JR; Sarkar S; Hampton S; Riley J; Stojanovski L; Sahlberg C; Appelqvist P; Erath J; Mathan V; Rodriguez A; Kaiser M; Pacanowska DG; Read KD; Johansson NG; Gilbert IH
    J Med Chem; 2020 Mar; 63(6):3066-3089. PubMed ID: 32134269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
    Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studies.
    Soeiro Mde N; Dantas AP; Daliry A; Silva CF; Batista DG; de Souza EM; Oliveira GM; Salomão K; Batista MM; Pacheco MG; Silva PB; Santa-Rita RM; Barreto RF; Boykin DW; Castro SL
    Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():301-10. PubMed ID: 19753489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ergosterol biosynthesis and drug development for Chagas disease.
    Urbina JA
    Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():311-8. PubMed ID: 19753490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model.
    Valle-Reyes JS; Melnikov V; Dobrovinskaya O; Rodriguez-Hernández A; Wookee-Zea C; Pimientel-Rodrigez V; Rueda-Valdovinos G; Delgado-Enciso I; López-Lemus UA; Espinoza-Gómez F
    Exp Parasitol; 2017 Jan; 172():44-50. PubMed ID: 28011170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicity of oleoresins from the genus Copaifera in Trypanosoma cruzi: a comparative study.
    Izumi E; Ueda-Nakamura T; Veiga-Júnior VF; Nakamura CV
    Planta Med; 2013 Jul; 79(11):952-8. PubMed ID: 23824551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.